Clinical Drug Investigation

, Volume 13, Issue 4, pp 185–191 | Cite as

Defibrotide Treatment and Disease Progression in Patients with IgA Nephropathy and Impaired Renal Function at Diagnosis

  • Giovanni M. Frascà
  • Mauro Martello
  • Cristina Canova
  • Elisabetta Isola
  • Alba Vangelista
  • Vittorio Bonomini
Clinical Use


Defibrotide is an antithrombotic agent that is capable of increasing the synthesis and release of prostaglandin I2 from endothelial cells, and improving fibrinolysis. The aim of this study was to evaluate the effectiveness of defibrotide therapy in slowing down the rate of progression of immunoglobulin (Ig) A nephropathy in patients with impaired renal function at diagnosis. 20 such patients were randomised to receive either prednisolone for 6 months plus defibrotide for 2 years (group A) or a 6-month prednisolone course only (group B). No significant difference was found at baseline between the two groups with regard to renal function, daily protein excretion or renal histological lesions. After 24 months, patients in group A had a mean decrease in serum creatinine level of 14%, compared with a 9% increase observed in group B (p = 0.007). A 14% increase in creatinine clearance occurred in group A patients as opposed to a 12% decrease in group B (p = 0.003). Daily protein excretion was significantly reduced in group A relative to baseline (p = 0.02), while it did not change in group B. These results suggest that nonimmunological factors are important in the progression of IgA nephropathy and that drugs that improve renal haemodynamics can contribute to the maintenance of renal function.


Serum Creatinine Level Drug Invest Renal Haemodynamics Eicosanoid Synthesis Thromboxane Synthetase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



This study was partly supported by a 1996 MURST and University of Bologna grant.


  1. 1.
    D’Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membrano-proliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315–23PubMedGoogle Scholar
  2. 2.
    Fassbinder W, Brunner FP, Brynger HB, et al. Combined report on regular dialysis and transplantation in Europe, 1989. Nephrol Dial Transplant 1991; 6: 34–5Google Scholar
  3. 3.
    Begenschutz O, Bohle A, Batz C, et al. IgA nephropathy: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 1990; 10: 137–47CrossRefGoogle Scholar
  4. 4.
    Van Es L. Pathogenesis of IgA nephropathy. Kidney Int 1992; 41: 1720–9PubMedCrossRefGoogle Scholar
  5. 5.
    Woo KT, Tan YO, Yap KH, et al. Beta-thromboglobulin in mesangial IgA nephritis. Thromb Res 1981; 24: 259–62PubMedCrossRefGoogle Scholar
  6. 6.
    Lee GSL, Lau YK, Woo KT, et al. Platelet factor 4 in IgA nephritis [letter]. Clin Nephrol 1991; 35: 44PubMedGoogle Scholar
  7. 7.
    Dohi K, Iwano M, Muraguchi A, et al. The prognostic significance of urinary interleukin 6 in IgA nephropathy. Clin Nephrol 1991; 35: 1–5PubMedGoogle Scholar
  8. 8.
    Coppo R, Amore A, Gianoglio B, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993; 21: 593–602PubMedGoogle Scholar
  9. 9.
    Gesualdo L, Emancipator SN, Kesselheim C, et al. Glomerular hemodynamics and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int 1992; 43: 106–14CrossRefGoogle Scholar
  10. 10.
    Coppo R, Roccatello D, Amore A, et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 1990; 33: 72–86PubMedGoogle Scholar
  11. 11.
    Clarkson AR, Seymour AE, Woodroffe AJ, et al. Controlled trial of phenytoin therapy in IgA nephropathy. Clin Nephrol 1980; 13: 215–8PubMedGoogle Scholar
  12. 12.
    Kobayashi Y, Fujii K, Hiki Y, et al. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 1988; 48: 12–7PubMedCrossRefGoogle Scholar
  13. 13.
    Frascà GM, Vangelista A, Martella D, et al. Prevention of chronic glomerular uremia in steroid resistant glomerulonephritis. A clinical trial with a new antithrombotic agent. Int J Artif Organs 1990; 13: 421–9PubMedGoogle Scholar
  14. 14.
    Palmer KJ, Goa KL. Defibrotide. A review of pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993; 45: 259–94PubMedCrossRefGoogle Scholar
  15. 15.
    Lianos EA, Andres GA, Dunn MJ. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. J Clin Invest 1983; 72: 1439–48PubMedCrossRefGoogle Scholar
  16. 16.
    Stahl RAK, Adler S, Baker PJ, et al. Enhanced glomerular prostaglandin formation in experimental membranous nephropathy. Kidney Int 1987; 31: 1126–31PubMedCrossRefGoogle Scholar
  17. 17.
    Rahman MA, Emancipator SN, Dunn MJ. Immune complex effects on glomerular eicosanoid production and renal hemodynamics. Kidney Int 1987; 31: 1317–26PubMedCrossRefGoogle Scholar
  18. 18.
    Cook HT, Cattel V, Smith J, et al. Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat. Clin Nephrol 1986; 26: 195–202PubMedGoogle Scholar
  19. 19.
    Purkerson ML, Joist JH, Yates J, et al. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 1985; 82: 193–7PubMedCrossRefGoogle Scholar
  20. 20.
    Yamashita W, Ito Y, Weiss MA, et al. A thromboxane synthetase antagonist ameliorates progressive renal disease of Dahl-S rats. Kidney Int 1988; 33: 77–83PubMedCrossRefGoogle Scholar
  21. 21.
    Donadio JV, Bergstrahl EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331: 1194–9PubMedCrossRefGoogle Scholar
  22. 22.
    Bennett WM, Walker G, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two year prospective trial. Clin Nephrol 1989; 31: 128–31PubMedGoogle Scholar
  23. 23.
    Cheng IKP, Chan PCK, Chan MK. The effect of fish oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 1990; 5: 241–6PubMedGoogle Scholar
  24. 24.
    Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3 polyunsaturated fatty acids: a prospective, double blind, randomised study. Clin Nephrol 1994; 41: 183–90PubMedGoogle Scholar
  25. 25.
    Donadio JV Jr. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 1991; 66: 1018–28PubMedGoogle Scholar
  26. 26.
    Fischer S, Weber PC. Thromboxane A3 (TxA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5ω3). Biochem Biophys Res Commun 1983; 116: 1091–9PubMedCrossRefGoogle Scholar
  27. 27.
    Sperling RI, Robin JL, Kylander KA, et al. The effects of N-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 1987; 139: 4186–91PubMedGoogle Scholar
  28. 28.
    Strieker RB, Reyes PT, Corash L, et al. A 210 glycoprotein that serves as a platelet Fc receptor. J Clin Invest 1987; 79: 1589–94CrossRefGoogle Scholar
  29. 29.
    Wardle EN. Cells and mediators in glomerulonephritis. Nephron 1988; 49: 265–76PubMedCrossRefGoogle Scholar
  30. 30.
    Camussi G. Potential role of platelet-activating factor in renal pathophysiology. Kidney Int 1986; 29: 469–77PubMedCrossRefGoogle Scholar
  31. 31.
    Barnes JL, Levine SP, Venkatachalam MA. Binding of platelet factor four (PF 4) to glomerular polyanion. Kidney Int 1984; 25: 759–65PubMedCrossRefGoogle Scholar
  32. 32.
    Camussi G, Tetta C, Coda R, et al. Platelet-activating factor-induced loss of glomerular anionic charges. Kidney Int 1984; 25: 73–81PubMedCrossRefGoogle Scholar
  33. 33.
    Abboud HE. Platelet-derived growth factor and mesangial cells. Kidney Int 1992; 41: 581–3PubMedCrossRefGoogle Scholar
  34. 34.
    Geualdo L, Pinzani M, Floriano JJ, et al. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab Invest 1991; 65: 160–7Google Scholar
  35. 35.
    Woo KT, Lee GSL, Lau YK, et al. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 1991; 36: 60–6PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Giovanni M. Frascà
    • 1
  • Mauro Martello
    • 1
  • Cristina Canova
    • 1
  • Elisabetta Isola
    • 1
  • Alba Vangelista
    • 1
  • Vittorio Bonomini
    • 1
  1. 1.Institute of Nephrology, St Orsola University HospitalBolognaItaly

Personalised recommendations